• Full Prescribing Information
  • Important Safety Information
  • Medication Guide
  • Visit Patient Site
  • About Spritam®
    • Why Choose Spritam?
    • Dosing and Administration
    • Bioavailability and Pk
    • Storage and Portability
  • Clinical Considerations
    • Clinical Factors to Consider
    • Identifying Swallowing Issues
  • Zipdose®  Technology
    • What is Zipdose® Technology?
    • Manufactured Using 3D Printing
  • Resources & FAQ
    • Prescribing Spritam
    • Frequently Asked Questions
Request samples



  • About Spritam®
    • What is SPRITAM?
    • Taking SPRITAM
    • Carrying and Storing SPRITAM
  • Understanding Epilepsy
    • Understanding Epilepsy
    • Your Experience Matters
    • Empowering Caregivers
  • Zipdose® Technology
    • What is ZipDose Technology?
    • Making Medicine Using 3D Printing
  • Savings and Support
    • Savings Program
    • Frequently Asked Questions
    • Information For Caregivers
  • About Spritam®
    • Why Choose Spritam?
    • Dosing and Administration
    • Bioavailability and Pk
    • Storage and Portability
  • Clinical Considerations
    • Clinical Factors to Consider
    • Identifying Swallowing Issues
  • Zipdose®  Technology
    • What is Zipdose® Technology?
    • Manufactured Using 3D Printing
  • Resources & FAQ
    • Prescribing Spritam
    • Frequently Asked Questions
  • Full Prescribing Information
  • Important Safety Information
  • Medication Guide
  • Visit Patient Site

Site Map



About SPRITAM

What is SPRITAM?

Talking SPRITAM

Carrying and Storing SPRITAM



Understanding Epilepsy

Understanding Epilepsy

Your Experience Matters

Empowering Caregivers



ZipDose® Technology

What is Zipdose® Technology?

Making Medicine Using 3D Printing



For Caregivers

Information For Caregivers



Savings and Support

Saving Program

Frequently Asked Questions



Full Prescribing Information

Important Safety Information

Medication Guide

Terms of Use

Privacy Policy

Indications and Usage

SPRITAM (levetiracetam) is a prescription medicine used to treat partial-onset seizures in patients 4 years of age and older. SPRITAM is also used as adjunctive therapy to treat myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. SPRITAM is recommended for use in patients weighing more than 44 pounds (20 kilograms).

Important Safety Information

SPRITAM may not be for everyone. SPRITAM is contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema.

Warnings and Precautions

SPRITAM may cause behavioral abnormalities including psychotic symptoms, suicidal ideation, irritability and aggressive behavior. Patients treated with SPRITAM should be monitored for psychiatric signs and symptoms.

Antiepileptic drugs, including SPRITAM, may cause suicidal thoughts or actions in a very small number of patients, about 1 in 500. Advise patients to contact you right away if they experience new or worsening symptoms of depression, any unusual changes in mood or behavior, or suicidal thoughts, behavior, or thoughts about self-harm they have never had before or which may be worse than before.

SPRITAM may cause extreme sleepiness, tiredness, and weakness, and problems with muscle coordination. Patients should be instructed not to drive, operate machinery or do other dangerous activities until they know how SPRITAM affects them.

SPRITAM can cause anaphylaxis or angioedema after the first dose or at any time during treatment. Advise your patients to discontinue SPRITAM and seek immediate medical attention if they have allergic reactions such as swelling of the face, lips, eyes, tongue and throat, trouble swallowing or breathing, and hives.

Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), can occur after your patients start taking SPRITAM. There is no way to tell if a mild rash will become a serious reaction. SPRITAM should be discontinued at the first sign of rash unless clearly not drug related.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, can occur in patients taking SPRITAM, and can be fatal or life-threatening, particularly if diagnosis and treatment do not occur as early as possible. DRESS may present with symptoms of fever, rash, lymphadenopathy and/or facial swelling associated with signs of other organ system involvement (e.g., hepatitis, nephritis, myocarditis, myositis, or hematological abnormalities [eosinophilia]). Advise your patients to seek immediate medical attention if any of these symptoms develop. SPRITAM should be discontinued immediately if a serious hypersensitivity reaction is suspected.

Advise patients not to stop SPRITAM unless instructed by you. Stopping a seizure medication suddenly can cause more frequent seizures or seizures that will not stop.

SPRITAM can cause hematologic abnormalities. A complete blood count is recommended in patients experiencing significant weakness, pyrexia, recurrent infections, or coagulation disorders.

Instruct patients to contact you right away if they become pregnant or intend to become pregnant.

Common Adverse Reactions

In clinical trials, the most common side effects seen in adults who take SPRITAM include sleepiness, weakness, dizziness, and infection. In addition to those previously listed, the most common side effects seen in children who take SPRITAM include tiredness, acting aggressive, nasal congestion, decreased appetite, and irritability.

To report SUSPECTED ADVERSE REACTIONS, contact Aprecia Pharmaceuticals, LLC at 1-844-882-7732 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Administration

SPRITAM is intended to disintegrate in the mouth when taken with a sip of liquid, one tablet at a time. As a primary method of administration, instruct patients to place a tablet on their tongue with a dry hand, and then take a sip of liquid. SPRITAM should be swallowed only after the tablet disintegrates in the mouth. SPRITAM should not be swallowed intact. Partial tablet(s) should not be administered.

Alternately, patients can add whole SPRITAM tablet(s) to a small volume of liquid in a cup (one tablespoon or enough to cover the medicine), swirl gently and swallow immediately after the tablet(s) disintegrate. If there is any medicine left in the cup, instruct patients to rinse with a small volume of liquid, swirl and swallow the remaining contents.

SPRITAM may also be administered via nasogastric or gastrostomy feeding tube (French size 10 to 14). Place the required number of whole tablets in a dosing cup with approximately 10 mL of room temperature water and gently swirl until the tablets disperse. Draw up the mixture into a 10 mL oral catheter-tip syringe, hold the syringe vertically, and administer immediately via feeding tube. Flush the feeding tube twice after administration by repeating this method with an additional 10 mL of room temperature water in the same dosing cup to ensure complete delivery of any remaining tablet residue, in the feeding tube.

 

For additional safety information, please see U.S. Full Prescribing Information and Medication Guide.

 

Manufactured by Aprecia Pharmaceuticals, LLC, Mason, OH 45040 USA Distributed by Prasco, LLC, Mason, OH 45040 USA

 

SPRITAM® is a registered trademark of Aprecia Pharmaceuticals, LLC.

© 2025 Prasco LLC all rights reserved.

 

LB-SI-0002.F

Revised 07/2025

PP-MA-SP-US-0206

For questions about SPRITAM, call 844-SPRITAM (844-777-4826).

SPRITAM® and ZipDose® are registered trademarks of Aprecia Pharmaceuticals, LLC.

KEPPRA® is a registered trademark of the UCB Group of companies.

Manufactured by Aprecia Pharmaceuticals, LLC, Mason, Ohio 45040 USA.

Distributed by Prasco, LLC, Mason, Ohio 45040 USA.

  • Privacy Policy
  • Terms of Use
  • Site Map
  • References

© Prasco, LLC. All rights reserved. PP-MA-SP-US-0025

Expand

Indications and Usage

SPRITAM (levetiracetam) is a prescription medicine used to treat partial-onset seizures in patients 4 years of age and older. SPRITAM is also used as adjunctive therapy to treat myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. SPRITAM is recommended for use in patients weighing more than 44 pounds (20 kilograms).

Important Safety Information

SPRITAM may not be for everyone. SPRITAM is contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema.

Warnings and Precautions

SPRITAM may cause behavioral abnormalities including psychotic symptoms, suicidal ideation, irritability and aggressive behavior. Patients treated with SPRITAM should be monitored for psychiatric signs and symptoms.

Antiepileptic drugs, including SPRITAM, may cause suicidal thoughts or actions in a very small number of patients, about 1 in 500. Advise patients to contact you right away if they experience new or worsening symptoms of depression, any unusual changes in mood or behavior, or suicidal thoughts, behavior, or thoughts about self-harm they have never had before or which may be worse than before.

SPRITAM may cause extreme sleepiness, tiredness, and weakness, and problems with muscle coordination. Patients should be instructed not to drive, operate machinery or do other dangerous activities until they know how SPRITAM affects them.

SPRITAM can cause anaphylaxis or angioedema after the first dose or at any time during treatment. Advise your patients to discontinue SPRITAM and seek immediate medical attention if they have allergic reactions such as swelling of the face, lips, eyes, tongue and throat, trouble swallowing or breathing, and hives.

Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), can occur after your patients start taking SPRITAM. There is no way to tell if a mild rash will become a serious reaction. SPRITAM should be discontinued at the first sign of rash unless clearly not drug related.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, can occur in patients taking SPRITAM, and can be fatal or life-threatening, particularly if diagnosis and treatment do not occur as early as possible. DRESS may present with symptoms of fever, rash, lymphadenopathy and/or facial swelling associated with signs of other organ system involvement (e.g., hepatitis, nephritis, myocarditis, myositis, or hematological abnormalities [eosinophilia]). Advise your patients to seek immediate medical attention if any of these symptoms develop. SPRITAM should be discontinued immediately if a serious hypersensitivity reaction is suspected.

Advise patients not to stop SPRITAM unless instructed by you. Stopping a seizure medication suddenly can cause more frequent seizures or seizures that will not stop.

SPRITAM can cause hematologic abnormalities. A complete blood count is recommended in patients experiencing significant weakness, pyrexia, recurrent infections, or coagulation disorders.

Instruct patients to contact you right away if they become pregnant or intend to become pregnant.

Common Adverse Reactions

In clinical trials, the most common side effects seen in adults who take SPRITAM include sleepiness, weakness, dizziness, and infection. In addition to those previously listed, the most common side effects seen in children who take SPRITAM include tiredness, acting aggressive, nasal congestion, decreased appetite, and irritability.

To report SUSPECTED ADVERSE REACTIONS, contact Aprecia Pharmaceuticals, LLC at 1-844-882-7732 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Administration

SPRITAM is intended to disintegrate in the mouth when taken with a sip of liquid, one tablet at a time. As a primary method of administration, instruct patients to place a tablet on their tongue with a dry hand, and then take a sip of liquid. SPRITAM should be swallowed only after the tablet disintegrates in the mouth. SPRITAM should not be swallowed intact. Partial tablet(s) should not be administered.

Alternately, patients can add whole SPRITAM tablet(s) to a small volume of liquid in a cup (one tablespoon or enough to cover the medicine), swirl gently and swallow immediately after the tablet(s) disintegrate. If there is any medicine left in the cup, instruct patients to rinse with a small volume of liquid, swirl and swallow the remaining contents.

SPRITAM may also be administered via nasogastric or gastrostomy feeding tube (French size 10 to 14). Place the required number of whole tablets in a dosing cup with approximately 10 mL of room temperature water and gently swirl until the tablets disperse. Draw up the mixture into a 10 mL oral catheter-tip syringe, hold the syringe vertically, and administer immediately via feeding tube. Flush the feeding tube twice after administration by repeating this method with an additional 10 mL of room temperature water in the same dosing cup to ensure complete delivery of any remaining tablet residue, in the feeding tube.

 

For additional safety information, please see U.S. Full Prescribing Information and Medication Guide.

 

Manufactured by Aprecia Pharmaceuticals, LLC, Mason, OH 45040 USA Distributed by Prasco, LLC, Mason, OH 45040 USA

 

SPRITAM® is a registered trademark of Aprecia Pharmaceuticals, LLC.

© 2025 Prasco LLC all rights reserved.

 

LB-SI-0002.F

Revised 07/2025

PP-MA-SP-US-0206

Terms and Conditions

SPRITAM SERVE Savings Program

In order to participate in the SPRITAM SERVE Savings Program (“Program”), you must have a valid prescription for SPRITAM® (levetiracetam) Tablets for Oral Suspension and meet the eligibility requirements set forth herein. By using this Program, the user certifies that he or she (i) is over the age of 18, (ii) is the patient or the patient’s caregiver and has the patient’s consent to use this offer, and (iii) meets the eligibility criteria and will comply with the terms and conditions of the Program set forth below.  Patients with questions about the Program should call (844) 777-4826.  The Program consists of three separate offerings, each of which has certain unique eligibility requirements and limitations, as further described below.  Each patient is limited to one Program offering and none of the Program offerings may be combined.

A. Retail Pharmacy Electronic Voucher (e-voucher) Program

The SPRITAM SERVE E-voucher can be applied to eligible claims at retail pharmacies who participate in Relay Health’s e-voucher programs. The e-voucher will be automatically applied to eligible prescriptions at the time of adjudication by Relay Health through the participating pharmacy. The E-voucher is available to:

  1. Commercially insured patients whose plan covers SPRITAM with a co-pay that exceeds $10 for a 30-day supply. For such patients, Prasco, LLC buys down a one-month, 60-tablet supply to a patient co-pay as low as $10. The maximum SPRITAM SERVE E-voucher amount for 60 tablets is $390 per 30-day supply for commercially covered claims.
  2. Commercially insured patients whose plan does not cover SPRITAM. For such patients, Prasco, LLC buys down a one-month, 60-tablet supply to as low as $75. The SPRITAM SERVE E-voucher offers a maximum benefit of $2,000 per patient per calendar year for uncovered patients.

The patient is responsible for any costs once these limits are reached.

The SPRITAM SERVE E-voucher is not available to uninsured patients.

B. Spritam Serve Savings Coupon (“Coupon”)

The SPRITAM SERVE Coupon can be applied to eligible claims . Patients must present the Coupon card to the pharmacist along with a valid SPRITAM prescription.  The Coupon is available to:

  1. Commercially insured patients whose plan covers SPRITAM with a co-pay that exceeds $10 for a 30-day supply. For such patients, Prasco, LLC buys down a one-month, 60 tablet supply to a patient co-pay as low as $10. The Coupon is limited to 12 fills per calendar year for commercially covered claims. The SPRITAM SERVE Coupon offers a maximum benefit of $5,000 per patient per calendar year for insured patients with coverage for SPRITAM.
  2. Commercially insured patients whose plan does not cover SPRITAM or uninsured patients. For such patients, Prasco, LLC buys down a one-month 60-tablet supply to a patient co-pay as low as $10. The SPRITAM SERVE Coupon offers a maximum benefit of $2,500 per patient per calendar year for uncovered or uninsured patients.

The patient is responsible for any costs once these limits are reached.

C. Blink Health Specialty Pharmacy Savings Program

Prasco, LLC has partnered with Blink Health Pharmacy, LLC (“Blink Health”) to offer savings to commercially insured patients.  SPRITAM prescriptions eligible for The SPRITAM SERVE Blink Health must be filled and dispensed by Blink Health or one of its participating partner pharmacies.  The SPRITAM SERVE Blink Health offering is available to:

  1. Commercially insured patients whose plan covers SPRITAM with a co-pay that exceeds $10 for a 30-day supply. For such patients, Prasco, LLC buys down a one-month, 60 tablet supply to a patient co-pay as low as $10.
  2. Commercially insured patients whose plan does not cover SPRITAM or uninsured patients. For such patients, Prasco, LLC buys down a one-month 60-tablet supply to a patient co-pay as low as $75.

The SPRITAM SERVE Blink Health offerings offers a maximum benefit of $5,000 per patient per calendar year.  The patient is responsible for any costs once these limits are reached.

General Spritam Serve Savings Program Terms and Conditions

The following terms and conditions are applicable to each offering under the Program.

Patient savings may vary based on insurance coverage and tablet amount.  Prescriptions must be written to a pharmacy that has elected to participate in the applicable Program offering.  Maximum coverage limits and exclusions apply and vary by savings vehicle as described above in sections A, B and C. The Program is good for a maximum of 365 days of therapy (limited to 60 tablets per month) over 12 months and will renew for an additional 12-months after the conclusion of each 12-month period.   The patient is responsible for any costs once the applicable limit is reached during the applicable period.  The Program is subject to change at any time.

The Program is not valid (i) for use by patients who are covered by any federal or state funded health care program (including, but not limited to, Medicare, Medicaid, TRICARE, VA or DoD), or (ii) where the patient’s insurance plan reimburses for the entire cost of the drug. The value of this Program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations. The Program is not valid where prohibited by law. The patient may not seek reimbursement for the value received from this offer from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. The patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the savings Program. Valid only in the United States where copay savings programs are allowable by law. This offer is not health insurance. Offer may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required.  By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions of the Program.

Prasco, LLC reserves the right to rescind, revoke or amend this program without notice at any time.